Ultimovacs Announces Plenary Oral Presentation of Phase I

0
74


  • New scientific information from part I trial UV1-103, combining UV1 with pembrolizumab in superior melanoma shall be introduced

Oslo, September 21 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a scientific stage chief in immune stimulatory vaccines for most cancers, introduced as we speak that additional information from its scientific examine on the mixture of its common most cancers vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, shall be disclosed in an oral presentation on the 19th International Congress of the Society for Melanoma Research (SMR) on 18 October 2022.

The presenter shall be Dr. Yousef Zakharia, Investigator for the UV1-103 scientific trial. Dr. Zakharia is a Medical Oncologist, Clinical Associate Professor and Director Phase I Program at University of Iowa Hospital and Clinics.

“I am pleased to present the results from the UV1-103 trial to international peers in melanoma research”, stated Dr. Yousef Zakharia. Carlos de Sousa, CEO of Ultimovacs added: “As Ultimovacs’ five randomized phase II trials of UV1 continue to mature, there is growing interest in the ability of the vaccine to induce long-lasting, survival-associated immune responses. We are honored to be able to present further data on the clinical activity of UV1.”

Ultimovacs’ presentation is entitled ‘Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Unresectable Melanoma’ and shall be given as an oral presentation on the International Congress of the Society for Melanoma Research. Society for Melanoma Research shall be on-line and in-person in Edinburgh, UK, October 17 – 20, 2022. The congress brings collectively the leaders within the discipline of primary and translational melanoma analysis and melanoma scientific trial physicians from around the globe.

See also  Immutep Receives A$2.7 million R&D Tax Incentive from

The presentation shall be made accessible on the Company web site on October 18, 2022.

***

About the UV1-103 part I trial in Malignant Melanoma
This US-based Phase I scientific trial is evaluating the Company’s lead candidate, UV1, together with PD-1 checkpoint inhibitor, pembrolizumab, as a first-line remedy in sufferers with metastatic malignant melanoma. The scientific outcomes for the 30 sufferers enrolled are:

  • Objective response charge (ORR): 57%, full response charge (CR): 33%
  • Median Progression Free Survival (mPFS): 18.9 months (as measured by iRECIST)
  • Overall survival after 12 months: 87%, total survival after 24 months: 73%

Patients will proceed to be adopted for long-term survival. UV1 has demonstrated a very good security profile, and no surprising questions of safety associated to UV1 have been noticed on this trial.

The U.S. Food and Drug Administration (FDA) granted a twin Fast Track designation for UV1 together with checkpoint inhibitors within the remedy of unresectable or metastatic melanoma – both as add-on remedy to pembrolizumab or as add-on remedy to ipilimumab. Ultimovacs is at present evaluating UV1 as add-on remedy to ipilimumab and nivolumab as first-line remedy for unresectable or metastatic melanoma in a Phase II examine named INITIUM.

About Ultimovacs 
Ultimovacs is an immunotherapy firm growing immune-stimulatory vaccines to deal with a broad vary of cancers. Ultimovacs’ lead common most cancers vaccine candidate UV1 targets human telomerase (hTERT), current in 85-90% of cancers in all levels of tumor progress. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and improve anti-tumor responses. With a broad Phase II program in 5 most cancers indications enrolling greater than 650 sufferers, Ultimovacs goals to clinically reveal UV1’s impression in a number of most cancers sorts, together with different immunotherapies, for sufferers with unmet wants. Ultimovacs’ second know-how method, based mostly on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the identical molecule and entered Phase I research in 2021. 

See also  New Revolutionary Treatment Reduces Chronic Pain and Drastically Improves Quality Of Life

For additional info, please see www.ultimovacs.com or contact: 

Carlos de Sousa, CEO  
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507  

Anne Worsøe, Head of Investor Relations
Email: ir@ultimovacs.com
Phone: +47 906 86 815

Mary-Ann Chang, LifeSci Advisors 
Email: mchang@lifesciadvisors.com 
Phone: +44 7483 284 853 

 



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here